Estetrol and Drospirenone
Brand names: Nextstellis · Active ingredient: Drospirenone, Estetrol Monohydrate
In short: NEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use NEXTSTELLIS may be less effective in females with a BMI ≥ 30 kg/m2.
What is Estetrol and Drospirenone used for?
NEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy.
Limitations of Use
NEXTSTELLIS may be less effective in females with a BMI ≥ 30 kg/m2. In females with BMI ≥ 30 kg/m2, decreasing effectiveness may be associated with increasing BMI .
⚠ Boxed warning (FDA's strongest warning)
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in females over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NEXTSTELLIS, are contraindicated in females who are over 35 years of age and smoke.
Estetrol and Drospirenone dosage
Start NEXTSTELLIS using a Day 1 start. Take one tablet by mouth at the same time every day with or without food.
To achieve maximum contraceptive effectiveness, take one tablet every day at about the same time each day. The recommended dosage of NEXTSTELLIS is one tablet daily for 28 consecutive days: one pink active tablet daily during the first 24 days followed by one white inactive tablet daily during the 4 following days .
Starting NEXTSTELLIS in females with no current use of hormonal contraception | Important:
In females with irregular menstrual cycles, pregnancy testing may be necessary prior to initiation of this product.
Day 1 Start:
Take the first pink active tablet on the first day of menses.
Take subsequent pink active tablets once daily at the same time each day for a total of 24 days.
Take one white inert tablet daily for 4 days and at the same time of day that active tablets were taken.
Begin each subsequent 28-day pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last tablet)
If not starting on the first day of menses, use a non-hormonal contraceptive (e.g. condoms and/or spermicide) as back-up until one active tablet has been taken daily for 7 days in a row.
Switching to NEXTSTELLIS from another contraceptive method | Start NEXTSTELLIS on the day:
Combined Oral Contraceptive (COC) | When the new pack of the previous COC would have started.
Transdermal System | When the next application would have been scheduled.
Vaginal Insert | When the next insertion would have been scheduled.
Injection | When the next injection would have been scheduled.
Intrauterine System (IUS) | After removal.
Implant | After removal.
Progestin-only pill | After the last tablet was taken.
Starting NEXTSTELLIS after delivery (>20 weeks gestation) | Must not start earlier than 4 weeks after delivery (due to the increased risk of thromboembolism
If menstrual cycles have returned, follow instructions for "Starting NEXTSTELLIS in females with no current use of hormonal contraception".If menstrual cycles have not resumed, consider the possibility of ovulation and pregnancy. If not pregnant, use additional nonhormonal contraception for the first 7 days of NEXTSTELLIS use.
Starting NEXTSTELLIS after Abortion or Miscarriage
≤14 weeks gestation | Within the first 7 days of complete first trimester abortion or miscarriage, use additional nonhormonal contraception for the next 7 days. After the first 7 days, follow instructions for "Starting NEXTSTELLIS in females with no current use of hormonal contraception".
> 14 weeks but ≤ 20 weeks gestation | After 4 weeks following second trimester abortion or miscarriage. …
How to take Estetrol and Drospirenone — instructions & advice from the label
Advise the patient to read the FDA-Approved patient labeling (Patient Information and Instructions of Use).
Sexually Transmitted Infections
Advise females that NEXTSTELLIS does not protect against HIV infection or other sexually transmitted infections.
Important Administration Instructions and Instructions for Missed Doses
Instruct females to take one tablet daily by mouth at the same time every day. Advise patients about what to do in the event that pills are missed .
Advise females starting NEXTSTELLIS to use additional nonhormonal contraception for 7 days after the first dose unless NEXTSTELLIS is started on the first day (Day 1) of menses
Advise females who miss more than two consecutive days of NEXTSTELLIS or experience vomiting or diarrhea for > 48 hours consecutively to use additional nonhormonal contraception for 7 days
Thromboembolic Disorders and Other Vascular Problems
. …
Warnings & precautions
Do not take this medicine if: NEXTSTELLIS is contraindicated in females who are known to have or develop the following conditions:
A history of, increased risk for, or current arterial or venous thrombotic/thromboembolic diseases. Examples include females who are known to:
-Smoke, if 35 years of age and older
-Have current or history of deep vein thrombosis or pulmonary embolism
-Have cerebrovascular disease
-Have coronary artery disease
-Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
-Have inherited or acquired hypercoagulopathies
-Have uncontrolled hypertension or hypertension with vascular disease
-Have diabetes mellitus with hypertension or end-organ damage; or diabetes mellitus of > 20 years duration
-Have migraine headaches with aura
Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive
Hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe (decompensated) cirrhosis
Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations
Abnormal uterine bleeding that has an undiagnosed etiology
Renal Impairment
Adrenal insufficiency
Stop NEXTSTELLIS if an arterial or venous thrombotic/thromboembolic event occurs.
Stop NEXTSTELLIS if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions and evaluate for retinal vein thrombosis immediately.
Discontinue NEXTSTELLIS during prolonged immobilization.
Start NEXTSTELLIS no earlier than four weeks after delivery in females who are not breast feeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the likelihood of ovulation increases after the third postpartum week. …
Estetrol and Drospirenone side effects
The following clinically significant adverse reactions with the use of COCs are discussed elsewhere in labeling:
Serious cardiovascular events including venous and arterial thromboembolism
Hyperkalemia
Liver disease
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data provided reflect the experience with the use of NEXTSTELLIS in two large prospective studies, one in Europe/Russia (C301) and one in North America (C302) (N = 3,632) of NEXTSTELLIS for the prevention of pregnancy in females 16-50 years of age. The mean duration of NEXTSTELLIS exposure was 317 and 257 days for the respective studies. The study population was 27 years of age on average, with a mean BMI of 25 kg/m2. The racial distribution was 83% White; 11% Black; 3% Asian; and 3% Other.
Preferred Term (PT) | Participants with Adverse Reaction –US/Canada Phase 3 trial (n [%])(N = 2073)Represents the safety population of C302 only (US/Canada). | Participants with Adverse Reaction –Two Phase 3 trials (n [%])(N=3632)Represents the safety population of C301/C302 for DRSP/E4.
Any adverse reactionAny adverse reaction equals any adverse event ≥ 2%. …
Drug interactions
Clinically significant drug interactions with other drugs that affect NEXTSTELLIS are presented in Table 5.
CYP3A Inducers
Clinical Effect | DRSP is a CYP3A4 substrate. Concomitant use with strong CYP3A inducers or certain moderate or weak CYP3A inducers may decrease DRSP exposure , which may lead to contraceptive failure.
Prevention or Management | Strong CYP3A Inducers | Avoid concomitant use. If concomitant use is unavoidable, use an alternative contraceptive method (e.g., intrauterine system) or backup non-hormonal contraceptive method during coadministration and up to 28 days after discontinuation of the strong CYP3A inducer.
Moderate and Weak CYP3A Inducers | Use an alternative or backup contraceptive method during coadministration and up to 28 days after discontinuation of the CYP3A inducer, unless the Prescribing Information of the specific moderate or weak CYP3A inducer indicates there is no clinically significant interaction with NEXTSTELLIS.
Strong CYP3A Inhibitors
Clinical Effect | DRSP is a CYP3A4 substrate. Concomitant use with a strong CYP3A inhibitor may increase DRSP exposure , which may increase the risk of adverse reactions of NEXTSTELLIS, including hyperkalemia . …
About this medicine
NEXTSTELLIS® (drospirenone and estetrol tablets) is an oral contraceptive. It is supplied in a transparent PVC/aluminum blister card containing 28 tablets:
24 pink active tablets contain 3 mg drospirenone and 14.2 mg of estetrol on the anhydrous basis. Drospirenone is a synthetic progestin and estetrol is a synthetic estrogen.
4 white inert tablets.
The chemical name for estetrol is estra-1,3,5(10)-triene-3,15α,16α,17α-tetrol monohydrate. It has a molecular formula of C18H24O4∙H2O and a molecular weight of 322.4 g/mol, equivalent to 304.4 g/mol (anhydrous). Estetrol has the following chemical structure:
Estetrol (monohydrate) is a white to off-white crystalline solid that is poorly soluble in water and aqueous solutions. It is soluble in methanol, ethanol, sparingly soluble in acetone, and slightly soluble in ethyl acetate and acetonitrile.
Drospirenone is chemically described as (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro10,13-dimethylspiro-[17H-dicyclopropa-[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5H)-furan]-3,5'(2H)-dione). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c5270073-d083-4109-ae4b-156986175e0a. Read the full official label on DailyMed.